Literature DB >> 16466690

Oxidized low density lipoprotein suppresses lipopolysaccharide-induced inflammatory responses in microglia: oxidative stress acts through control of inflammation.

Ohn Soon Kim1, Chang Seok Lee, Eun-hye Joe, Ilo Jou.   

Abstract

Low density lipoprotein (LDL) is readily oxidized under certain conditions, resulting in the formation of oxidized LDL (oxLDL). Despite numerous in vitro reports that reveal the pathogenic role of oxidative stress, anti-oxidative strategies have underperformed in the clinic. In this study, we examine the role of oxLDL in brain inflammatory responses using cultured rat brain microglia. We demonstrate that oxLDL inhibits lipopolysaccharide (LPS)-induced inflammatory responses in these cells. It also decreases LPS-induced expression of inducible nitric oxide synthase and production of nitric oxide, and reduces LPS-induced secretion of tumor necrosis factor-alpha and monocyte chemoattractant protein-1. Oxysterols, known components of oxLDL and endogenous agonists of liver X receptor, can simulate the inhibitory effects of oxLDL in LPS-activated microglia. In addition, their inhibitory effects were mimicked by liver X receptor (LXR) agonists and potentiated by a retinoid X receptor agonist, suggesting these molecules heterodimerize to function as oxysterol receptors. Taken together, our results demonstrate that oxLDL inhibits LPS-induced inflammatory responses in brain microglia and that these inhibitory effects are mediated by oxysterols and, at least in part, by the nuclear receptor LXR. Our results suggest an additional mechanism of action for oxidative stress that acts indirectly via modulation of inflammatory responses. Although further studies are needed, these results answer in part the question of why anti-oxidative strategies have not been successful in clinical situations. Moreover, as brain inflammation participates in the initiation and progression of several neurodegenerative disorders, the present data provide information that should prove a useful guide for designing therapeutic strategies to combat oxidative brain diseases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16466690     DOI: 10.1016/j.bbrc.2006.01.107

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  12 in total

1.  Cholesterol-metabolizing enzyme cytochrome P450 46A1 as a pharmacologic target for Alzheimer's disease.

Authors:  Natalia Mast; Aicha Saadane; Ana Valencia-Olvera; James Constans; Erin Maxfield; Hiroyuki Arakawa; Young Li; Gary Landreth; Irina A Pikuleva
Journal:  Neuropharmacology       Date:  2017-06-24       Impact factor: 5.250

2.  Resveratrol attenuates oxidized LDL-evoked Lox-1 signaling and consequently protects against apoptotic insults to cerebrovascular endothelial cells.

Authors:  Huai-Chia Chang; Tyng-Guey Chen; Yu-Ting Tai; Ta-Liang Chen; Wen-Ta Chiu; Ruei-Ming Chen
Journal:  J Cereb Blood Flow Metab       Date:  2010-10-13       Impact factor: 6.200

3.  Diet and age interactions with regards to cholesterol regulation and brain pathogenesis.

Authors:  Romina M Uranga; Jeffrey N Keller
Journal:  Curr Gerontol Geriatr Res       Date:  2010-04-11

4.  Treatment with LXR agonists after focal cerebral ischemia prevents brain damage.

Authors:  Luigi Sironi; Nico Mitro; Mauro Cimino; Paolo Gelosa; Uliano Guerrini; Elena Tremoli; Enrique Saez
Journal:  FEBS Lett       Date:  2008-09-19       Impact factor: 4.124

Review 5.  Liver X receptors: from cholesterol regulation to neuroprotection-a new barrier against neurodegeneration in amyotrophic lateral sclerosis?

Authors:  Kevin Mouzat; Cédric Raoul; Anne Polge; Jovana Kantar; William Camu; Serge Lumbroso
Journal:  Cell Mol Life Sci       Date:  2016-08-10       Impact factor: 9.261

6.  Liver X receptor-dependent inhibition of microglial nitric oxide synthase 2.

Authors:  Julie R Secor McVoy; Hanadi Ajam Oughli; Unsong Oh
Journal:  J Neuroinflammation       Date:  2015-02-10       Impact factor: 8.322

7.  Treatment with TO901317, a synthetic liver X receptor agonist, reduces brain damage and attenuates neuroinflammation in experimental intracerebral hemorrhage.

Authors:  Chun-Hu Wu; Chien-Cheng Chen; Chai-You Lai; Tai-Ho Hung; Chao-Chang Lin; Min Chao; Szu-Fu Chen
Journal:  J Neuroinflammation       Date:  2016-03-11       Impact factor: 8.322

8.  Oxysterol levels and metabolism in the course of neuroinflammation: insights from in vitro and in vivo models.

Authors:  Valentin Mutemberezi; Baptiste Buisseret; Julien Masquelier; Owein Guillemot-Legris; Mireille Alhouayek; Giulio G Muccioli
Journal:  J Neuroinflammation       Date:  2018-03-09       Impact factor: 8.322

9.  Attenuation of neuroinflammation and Alzheimer's disease pathology by liver x receptors.

Authors:  Noam Zelcer; Negar Khanlou; Ryan Clare; Qingguang Jiang; Erin G Reed-Geaghan; Gary E Landreth; Harry V Vinters; Peter Tontonoz
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-11       Impact factor: 11.205

Review 10.  Oxysterols in Autoimmunity.

Authors:  Donovan Duc; Solenne Vigne; Caroline Pot
Journal:  Int J Mol Sci       Date:  2019-09-12       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.